DCF Tool


Amedisys Inc. – Home Health Care Services
amedisys is a leading provider of healthcare in the home with a vision of becoming the premiere solution for patients across the country to age in place. from home health to hospice to personal care, amedisys team members provide quality, clinically-distinctive care to more than 376,000 patients every year. every life is precious and tells an incredible story, and we celebrate that each day by honoring our patients with genuine, personal attention. everything we do, from the boardroom to our nationwide network of care centers, is centered on the best care possible for those who have entrusted us with their well-being and comfort. we work closely with doctors and other healthcare providers to coordinate services, and every patient has an individual plan of care that meets their specific needs. amedisys recognizes that nothing we do is possible without our incredible team. for all employees, whether they’re on the front lines delivering direct care or supporting our clinical team, this i
Analysis Results
Intrinsic Value $213.33
Latest Price $94.00
Relative Value 56% undervalued
Thoughts on this result? Let us know.
Cash Flow (Millions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 16.1%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 7.4%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 16.1%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 248 231
2024 288 250
2025 334 270
2026 388 292
2027 450 316
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 8580 million. This corresponds to a present value of 5600 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 1360 million. Adding in the terminal value gives a total present value of 6960 million.

There are presently 32.6 million outstanding shares, so the intrinsic value per share is 213.33.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 388,961,000
Current Cash 40,540,000
Current Liabilities 355,529,000
Current Debt 15,496,000
Non-Cash Working Capital (NCWC) 8,388,000
Change in NCWC 55,685,000
EBIT 183,736,000
Tax Provision 42,545,000
Depreciation and Amortization 24,935,000
Capital Expenditure -6,165,000
Unlevered Free Cash Flow 209,408,842
Current Assets 356,684,000
Current Cash 42,694,000
Current Liabilities 374,282,000
Current Debt 12,995,000
Non-Cash Working Capital (NCWC) -47,297,000
Change in NCWC 118,368,000
EBIT 243,564,000
Tax Provision 70,065,000
Depreciation and Amortization 30,901,000
Capital Expenditure -6,302,000
Unlevered Free Cash Flow 325,633,698
Current Assets 361,984,000
Current Cash 81,808,000
Current Liabilities 456,337,000
Current Debt 10,496,000
Non-Cash Working Capital (NCWC) -165,665,000
Change in NCWC -168,909,000
EBIT 193,014,000
Tax Provision 25,635,000
Depreciation and Amortization 28,802,000
Capital Expenditure -5,332,000
Unlevered Free Cash Flow 24,105,038
Current Assets 350,554,000
Current Cash 30,294,000
Current Liabilities 326,943,000
Current Debt 9,927,000
Non-Cash Working Capital (NCWC) 3,244,000
Change in NCWC 20,219,000
EBIT 184,280,000
Tax Provision 42,503,000
Depreciation and Amortization 18,428,000
Capital Expenditure -7,888,000
Unlevered Free Cash Flow 169,076,598
Current Assets 224,118,000
Current Cash 20,229,000
Current Liabilities 222,476,000
Current Debt 1,612,000
Non-Cash Working Capital (NCWC) -16,975,000
Change in NCWC -37,344,000
EBIT 162,840,000
Tax Provision 38,859,000
Depreciation and Amortization 13,261,000
Capital Expenditure -6,558,000
Unlevered Free Cash Flow 92,398,514
Current Assets 311,156,000
Current Cash 86,363,000
Current Liabilities 215,062,000
Current Debt 10,638,000
Non-Cash Working Capital (NCWC) 20,369,000
Change in NCWC 11,784,000
EBIT 111,940,000
Tax Provision 50,118,000
Depreciation and Amortization 17,123,000
Capital Expenditure -10,707,000
Unlevered Free Cash Flow 60,707,580
Current Assets 214,910,000
Current Cash 30,197,000
Current Liabilities 181,348,000
Current Debt 5,220,000
Non-Cash Working Capital (NCWC) 8,585,000
Change in NCWC 31,017,000
EBIT 67,360,000
Tax Provision 23,935,000
Depreciation and Amortization 19,678,000
Capital Expenditure -15,717,000
Unlevered Free Cash Flow 76,150,467
Current Assets 175,263,000
Current Cash 27,502,000
Current Liabilities 175,193,000
Current Debt 5,000,000
Non-Cash Working Capital (NCWC) -22,432,000
Change in NCWC 365,000
EBIT 77,925,000
Tax Provision 2,004,000
Depreciation and Amortization 20,036,000
Capital Expenditure -21,429,000
Unlevered Free Cash Flow 76,897,000
Current Assets 135,558,000
Current Cash 8,032,000
Current Liabilities 162,323,000
Current Debt 12,000,000
Non-Cash Working Capital (NCWC) -22,797,000
Change in NCWC 87,739,000
EBIT 30,145,000
Tax Provision 7,671,000
Depreciation and Amortization 28,347,000
Capital Expenditure -12,008,000
Unlevered Free Cash Flow 123,198,863
Current Assets 205,279,000
Current Cash 17,303,000
Current Liabilities 312,416,000
Current Debt 13,904,000
Non-Cash Working Capital (NCWC) -110,536,000
Change in NCWC -132,799,000
EBIT 6,041,000
Tax Provision -58,773,000
Depreciation and Amortization 37,383,000
Capital Expenditure -41,736,000
Unlevered Free Cash Flow -131,111,000
Current Assets 205,788,000
Current Cash 14,545,000
Current Liabilities 204,787,000
Current Debt 35,807,000
Non-Cash Working Capital (NCWC) 22,263,000
Change in NCWC 26,097,000
EBIT 51,593,000
Tax Provision -21,397,000
Depreciation and Amortization 40,059,000
Capital Expenditure -48,262,000
Unlevered Free Cash Flow 69,487,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.